Recent developments in glycopeptide antibacterials

Current Opinion in Investigational Drugs

Volumn 6, Issue 8, 2005, Pages 781-790

  Barrett, John F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antibacterial; Dalbavancin; Glycopeptides; Oritavancin; Resistance emergence; Telavancin

Indexed keywords

A 40926; A 82846B; AC 98 1; AC 98 6446; AMINOTRANSFERASE; ANTIBIOTIC AGENT; CEFALEXIN; CEFAZOLIN; DALBAVANCIN; LINEZOLID; LY 262826; MERSACIDIN; METICILLIN; MOXIFLOXACIN; ORITAVANCIN; PENICILLIN G; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; RAMOPLANIN; TEICOPLANIN; TELAVANCIN; THRX 689909; UNCLASSIFIED DRUG; VANCOMYCIN;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHLEBITIS; PNEUMONIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES; HUMANS;

EID: 23344448752     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Bassetti M, Melica G, Di Biagio A, Righi E, Rosso R, Bassetti D: New antibiotics for treatment of serious infections due to antibiotic-resistant Gram-positive cocci. Rev Med Microbiol (2004) 15(3):109-117.
2. Woodford N: Epidemiology of genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist (2001) 7(3):229-236.
3. Linden PK: Treatment options for vancomycin-resistant enterococcal infections. Drugs (2002) 62(3):425-441.
4. Ziglam HM, Finch RG: Limitations of presently available glycopeptides in the treatment of Gram-positive infection. Clin Microbiol Infect (2001) 7(Suppl 4):53-65.
5. Pootoolal J, Neu J, Wright GD: Glycopeptide antibiotic resistance. Annu Rev Pharmacol Toxicol (2002) 42:381-408.
6. Esposito S, Noviello S: What is the role of glycopeptides in intensive care? J Chemother(2003) 15(Suppl 3):11-16.
7. Malabarba A, Nicas TI, Ciabatti R: Glycopeptide resistance in multiple antibiotic-resistant Gram-positive bacteria: A current challenge for novel semi-synthetic glycopepticle derivatives. Eur J Med Chem (1997) 32(6):459-478.
8. Courvalin P: Genetics of glycopeptide resistance in Gram-positive pathogens. Int J Med Microbiol (2005) 294(8):479-486.
9. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, Kolonay JF, Shetty J, Kilgore GE, Tenover FC: Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science (2003) 302(5650):1569-1571.
10. Tenover FC, Biddle JW, Lancaster MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis (2001) 7(2):327-332.
11. Linares J: The VISA/GISA problem: Therapeutic implications. Clin Microbiol Infect (2001) 7(Suppl 4):8-15.
12. Gonzalez-Zorn B, Courvalin P: VanA-medlated high-level glycopeptide resistance in MRSA. Lancet Infect Dis (2003) 3(2):67-68.
13. Hiramatsu K: Vancomycin-resistent Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect Dis (2001) 1(3):147-155.
14. Kacica M; McDonald LC: Brief report: Vancomycin-resistant Staphylococcus aureus - New York, 2004. Morbidity and Mortality Report (2004) 53(15):322-323.
15. Pfeltz RF, Wilkinson BJ: The escalating challenge of vancomycin resistance in Staphylococcus aureus. Curr Drug Targets Infect Disord (2004) 4(4):273-294.
16. Srinivasan A, Dick JD, Perl TM: Vancomycin resistance in staphylococci. Clin Microbiol Rev (2002) 15(3):430-438.
17. Khare M, Keady D: Antimicrobial therapy of methicillin-resistant Staphylococcus aureus infection. Expert Opin Pharmacother (2003) 4(2):165-177.
18. Long TE: Recent progress towards the clinical development of new anti-MRSA antibiotics. IDrugs (2003) 6(4):351-359.
19. Abbanat D, Macielag M, Bush K: Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin Investig Drugs (2003) 12(3):379-399.
20. Woodford N: Novel agents for the treatment of resistant Gram-positive infections. Expert Opin Investig Drugs (2003) 12(3):117-137.
21. Rybak MJ: Therapeutic options for Gram-positive infections. J Hosp Infect (2001) 49(Suppl A):S25-S32.
22. Kauffman CA: Therapeutic and preventive options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother (2003) 51(Suppl 3):23-30.
23. InterMune Inc: InterMune development pipeline: Oritavacin. Company Website (2005): May 25. http://www.intermune.com/wt/itmn/development.pipeline
24. Montecalvo MA: Ramoplanin: A novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infections in high-risk patients. J Antimicrob Chemother (2003) 51(Suppl S3):iii31-iii35.
25. Malabarba A, Ciabatti R: Glycopeptide derivatives. Curr Med Chem (2001) 8(14):1759-1773.
26. Van Bambeke F, Van Laehem Y, Courvalin P, Tulkens PM: Glycopeptide antibiotics: From conventional molecules to new derivatives. Drugs (2004) 64(9):913-936.
27. Preobrazhenskaya MN, Olsufyeva E: Patents on glycopeptides of the vancomycin family and their derivatives as antimicrobials: January 1999 - June 2003. Expert Opin Ther Pat (2004) 14(2):141-173.
28. Van Bambeke F: Glycopeptides in clinical development: Pharmacological profile and clinical perspectives. Curr Opin Pharmacol (2004) 4(5):471-478.
29. Hoechst Marion Roussel Ltd: Drug development pipeline: Teicoplanin. Company Communication (1999): April 20.
30. Ziglam HM, Finch RG: Limitations of presently available glycopeptides in the treatment of Gram-positive infection. Clin Microbiol Infect (2001) 7(Suppl 4):53-65.
31. Campoli-Richards DM, Brogden RN, Faulds D: Teicoplanin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs (1990) 40(3):449-486.
32. Boger DL: Vancomycin, teicoplanin, and ramoplanin: Synthetic and mechanistic studies. Med Res Rev (2001) 21(5):356-381.
33. Zhu J: Recent developments in reversing glycopeptide-resistant pathogens. Expert Opin Ther Pat (1999) 9(8):1005-1019.
34. Finch RG; Eliopoulos GM: Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother (2005) 55(Suppl 2):ii5-ii13.
35. Barna JC; Williams DH: The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol (1984) 38:339-357.
36. Reynolds PE: Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis (1989) 8(11):943-950.
37. Ge M, Chen Z, Onishi HR, Kohler J, Silver LL, Kerns R, Fukuzawa S, Thompson C, Kahne D: Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science (1999) 284(5413):507-511.
38. Beauregard DA, Williams DH, Gwynn MN, Knowles DJ: Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother (1995) 39(3):781-785.
39. Goldman RC, Baizman ER, Longley CB, Branstrom AA: Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding. FEMS Microbiol Lett (2000) 183(2):209-214.
40. Vollmerhaus PJ, Breukink E, Heck AJ: Getting closer to the real bacterial cell wall target: Biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics. Chemistry (2003) 9(7):1556-1565.
41. Sorbera LA, Castañer J: Telavancin hydrochloride. Glycopeptide antibiotic. Drugs Future (2004) 29(12):1211-1219.
42. Malabarba A, Donadio S: BI 397. Glycopeptide antibiotic. Drugs Future (1999) 24(8):839-846.
43. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q et al: Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2005) 49(3):1127-1134.
44. Judice JK, Pace J: Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett (2003) 13(23):4165-4168.
45. Cooper RD, Snyder NJ, Zweitel MJ, Staszak MA, Wilkie SC, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ, Huff BE, Thompson RC: Reductive alkylation of glycopeptide antibiotics: Synthesis and antibacterial activity. J Antibiot (Tokyo) (1996) 49(6):575-581.
46. Al-Nawas B, Swantes J, Shah PM: In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci. Infection (2000) 28(4):214-218.
47. Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE: In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother (1997) 41(10):2165-2172.
48. Fraise AP, Andrews J, Wise R: Activity of a new glycopeptide (LY333328) against enterococci and other resistant Gram-positive organisms. J Antimicrob Chemother (1997) 40(3):423-425.
49. Harland S, Tebbs SE, Elliott TS: Evaluation of the in vitro activity of glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. J Antimicrob Chemother(1998) 41(2):273-276.
50. Steiert M, Schmitz F-J: Dalbavancin (Biosearch Italia/veraicor). Curr Opin Invest Drugs (2002) 3(2):229-233.
51. Guay DR: Dalbavancin: An investigational glycopeptide. Expert Rev Anti-Infective Therapy (2004) 2(6):845-853.
52. Jones RN, Biedenbach DJ, Johnson DM, Pfaller MA: In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J Chemother(2001) 13(3):244-254.
53. Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F: In vitro and in vivo activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother (1999) 44(2):179-192.
54. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT: In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and Corynebacterium. Antimicrob Agents Chemother (2003) 47(6):1968-1971.
55. Malabarba A, Goldstein BP: Origin, structure and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother (2005) 55(Suppl 2):ii15-ii20.
56. Versicor Inc: Form 10-Q: Versicor Inc. Form 10-Q (2003): November 14.
57. Vicuron Pharmaceuticals Inc: Form 8-K: Vicuron Pharmaceuticals Inc. Form 8-K (2004): August 12.
58. Vicuron Pharmaceuticals Inc: Form 8-K: Vicuron Pharmaceuticals Inc. Form 8-K (2004): December 21
59. InterMune Inc: InterMune announces positive top-line phase III clinical trial results of oritavancin antibiotic for bacterial skin infections. Press Release (2003): June 11.
60. FDC Reports: InterMune oritavancin NDA delayed six months; FDA requests safety study. The Pink Sheets (2003) 65(48):14.
61. Barrett JF: Oritavancin. Eli Lilly & Co. Curr Opin Invest Drugs (2001) 2(8):1039-1044.
62. Patel R, Rouse MS, Piper KE, Cockerill FR 3rd, Steckelberg JM: In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis (1998) 30(2):89-92.
63. Allen NE, Le Toumeau DL, Hobbs JN Jr: The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J Antibiot (Tokyo) (1997) 50(8):677-684.
64. Allen NE, Nicas TI: Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev (2003) 26(5):511-532.
65. Schwalbe RS, McIntosh AC, Qaiyumi S, Johnson JA, Johnson RJ, Furness KM, Holloway WJ, Steele-Moore L: In vitro activity of LY333328, an investigational glycopeptide antibiotic against enterococci and staphylococci. Antimicrob Agents Chemother (1996) 40(10):2416-2419.
66. Zeckel ML, Preston DA, Allen BS: In vitro activities of LY333328 and comparative agents against nosocomial Gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob Agents Chemother(1997) 44(5):1370-1374.
67. Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG: Pharmacokinetics, safety and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis (2004) 50(2):95-102.
68. Wasilewski MM, Disch DP, McGill JM, Harris HW, O'Riordan W, Zeckel ML: Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin/skin structure infections. ICAAC (2001) 41:Abs UL-18.
69. InterMune Inc: InterMune updates timing of oritavancin NDA submission. Press Release (2003): November 21.
70. Leadbetter MR, Adams SM, Bazzini B, Fatheree PR, Karr DE, Krause KM, Lam BM, Linsell MS, Nodwell MB, Pace JL, Quast K et al: Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424). J Antibiot (Tokyo) (2004) 57(5):326-336.
71. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Kaniga K, Schmidt D, Benton BM, Humphrey P: Telavancin bactericidal activity against Staphylococcus aureus is mediated by multiple mechanisms. ICAAC (2004) 44:Abs C1-953.
72. King A, Phillips I, Kaniga K: Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother(2004) 53(5):797-803.
73. Nagarajan R: Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot (Tokyo) (1993) 46(8):1181-1195.
74. Pavlov AY, Preobrazhenskaya MN: Chemical modification of glycopeptide antibiotics [VC1]. Russ J Bioorg Chem (1998) 24(9):570-587.
75. Theravance Inc: Theravance announces results from FAST 2 - A phase 2 clinical study with investigational antibiotic telavancin. Press Release (2004): December 04.
76. Theravance: Theravance announces initiation of phase 3 clinical studies in hospital acquired pneumonia with investigational antibiotic telavancin. Press Release (2005): January 26.
77. Theravance: Theravance announces fast track designation for investigational antibiotic telavancin. Press Release (2005): March 28.
78. Walker S, Chen L, Hu Y, Rew Y, Shin D, Boger DL: Chemistry and biology of ramoplanin: A lipoglycodepsipeptide with potent antibiotic activity. Chem Rev (2005) 105(2):449-476.
79. Stiefel U, Pultz NJ, Helfand MS, Donskey CJ: Efficacy of oral ramoplanin for inhibition of intestinal colonization by vancomycin-resistant enterococci in mice. Antimicrob Agents Chemother (2004) 48(6):2144-2148.
80. Somner EA, Reynolds PE: Inhibition of peptidoglycan synthesis by ramoplanin. Antimicrob Agents Chemother (1990) 34(3):413-419.
81. Lo MC, Hongbin M, Branstrom A, Helm J, Yao N, Goldman R, Walker S: A new mechanism of action proposed for ramoplanin. J Am Chem Soc (2000) 122(1):3540-3541.
82. Hu Y, Helm JS, Chen L, Ye XY, Walker S: Ramoplanin inhibits bacterial transglycosylases by binding as a dimmer to lipid II. J Am Chem Soc (2003) 125(29):8736-8737.
83. Baden LR, Critchley IA, Sahm DF, So W, Gedde M, Porter S, Moellering RC Jr, Eliopoulos G: Molecular characterization of vancomycin-resistant enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin. J Clin Microbiol (2002) 40(4):1160-1163.
84. Oscient Pharmaceuticals Corp: Oscient Pharmaceuticals announces plans to pursue shorter five-day dosing of FACTIVE tablets for community-acquired pneumonia. Press Release (2004): July 19.
85. Sum PE, How D, Torres N, Petersen PJ, Lenoy EB, Weiss WJ, Mansour TS: Novel ether derivative of mannopeptimycin derivatives of glycopeptide, antibiotic. Bioorg Med Chem Lett (2003) 13(6):1151-1155.
86. Sum PE, How D, Torres N, Petersen PJ, Ashcroft J, Graziani EI, Koehn FE, Mansour TS: Synthesis and evaluation of ether and halogenated derivatives of mannopeptimycin glycopeptide antibiotics. Bioorg Med Chem Lett (2003) 13(16):2805-2808.
87. He H, Williamson RT, Shen B, Graziani EI, Yang HY, Sakya SM, Petersen PJ, Carter GT: Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J Am Chem Soc (2002) 124(33):9729-9736.
88. Walsh C, Freel Meyers CL, Losey HC: Antibiotic glycosyltransferases: Antibiotic maturation and prospects for reprogramming. J Med Chem (2003) 46(16):3425-3436.
89. Peterson PJ, Wang TZ, Dishin RG, Bradford PA: Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin α, and other antimicrobial agents against Gram-positive Isolates. Antimicrob Agents Chemother (2004) 48(3):739-746.
90. Ruzin A, Singh G, Severin A, Yang Y, Dushin RG, Sutherland AG, Minnick A, Greenstein M, May MK, Shlaes DM, Bradford PA: Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant Gram-positive bacteria. Antimicrob Agents Chemother (2004) 48(3):728-738.
91. Goldman RC, Gange D: Inhibition of transglycosylation involved in bacterial peptidoglycan synthesis. Curr Med Chem (2000) 7(8):801-820.
92. Losey HC, Peczuh MW, Chen Z, Eggert US, Dong SD, Pelczer I, Kahne D, Walsh CT: Tandem action of glycosyltransferases in the maturation of vancomycin and teicoplanin aglycones: Novel glycopeptides. Biochemistry (2001) 40(15):4745-4755.
93. Sussmuth RD, Wohlleben W: The biosynthesis of glycopeptide antibiotics - a model for complex, non-ribosomally synthesized, peptidic secondary metabolites. Appl Microbiol Biotechnol (2004) 63(4):344-350.
94. Kruger RG, Lu W, Oberthur M, Tao J, Kahne D, Walsh CT: Tailoring of glycopeptide scaffolds by the acyltransferase from the teicoplanin and A-40,926 blosynthetic operons. Chem Biol (2005) 12(1):131-140.
95. Walsh CT, Losey HC, Freel Meyers CL: Antibiotic glycosyltransferases. Biochem Soc Trans (2003) 31(3):487-492.
96. Daines AM, Maltman BA, Flitsch SL: Synthesis and modifications of carbohydrates, using biotransformations. Curr Opin Chem Biol (2004) 8(2):106-113.
97. Malabarba A, Nicas TI, Thompson RC: Structural modification of glycopeptide antibiotics. Med Res Rev (1998) 17(1):69-137.
98. Sosio M, Stinchi S, Beltrametti F, Lazzarini A, Donadio S: The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by Nonomuraea species. Chem Biol (2003) 10(6):541-549.
99. Wink JM, Kroppenstedt RM, Ganguli BN, Nadkarni SR, Schumann P, Seibert G, Stackebrandt E: Three new antibiotic producing species of the genus Amycolatopsis, Amycolatopsis balhimycina sp nov, A tolypomycina sp nov, A vancoresmycina sp nov, and the description of Amycolatopsis keratiniphila sub sp Kertiniphila sub sp nov and A keratiniphila sub sp nogabecina sub sp nov. Syst Appl Microbiol (2003) 26(1):38-46.
100. Wink J, Gandhi J, Kroppenstedt RM, Seibert G, Straubler B, Schumann P, Stackebrandt E: Amycolatopsis decaplanina sp nov, a novel member of the genus with unusual morphology. Int J Syst Evol Microbiol (2004) 54(1):235-239.
101. Baltz RH: Combinatorial glycosylation of glycopeptide antibiotics. Chem Biol (2002) 9(12):1268-1270.
102. Recktenwald J, Shawky R, Puk O, Pfennig F, Keller U, Wohlleben W, Pelzer S: Nonribosomal blosynthesis of vancomycin-type antibiotics: A heptapeptide backbone and eight peptide synthase modules. Microbiology (2002) 148(4):1105-1118.
103. Puk O, Huber P, Bischoff D, Recktenwald J, Jung G, Sussmuth RD, van Pee KH, Wohlleben W, Pelzer S: Glycopeptide biosynthesis in Amycolatopsis mediterranei DSM5908: Function of a halogenase and a haloperoxidase/perhydrolase. Chem Biol (2002) 9(2):225-235.